The American manufacturer will invest 130 million dollars (110 M €) in its Harmans site, located in Maryland, in the United States.
Catalent will add five advanced stage clinical and commercial manufacturing rooms to this facility for the production of cell and gene therapies.
The rooms are expected to be commissioned in the first half of 2022, bringing the total number of manufacturing rooms to[…]
–
